Only PC patients characterized by stage T1/2a N0/Nx, PSA levels <15 ng/mL, composite Gleason score ≤ 7, primary grade ≤ 3, and percentage of positive biopsy cores ≤ 50% of total cores and not undergoing current therapy. This evidence concerns the gene KLK3 and pachyonychia congenita.